comparemela.com

Latest Breaking News On - Neux capital - Page 1 : comparemela.com

Atantares has Completed Two Rounds of RMB100 Million Financing, and the Pre-A Round is led by Asia Green Fund

/PRNewswire/ Recently, Atantares announced the completion of Pre-A and Pre-A+ financing all around RMB100 million. The Pre-A round is led by Asia Green.

Kuan huangAlibaba healthFrees fundFosun health capitalAsia green fundQiming venture partnersNext capitalNeux capitalManaging director

China Digest: Rgenta Therapeutics, Taichu Biotech raise funding

Rgenta Therapeutics has snagged $60 million in a Series A round participated by Highlight Capital, while IDG Capital has led Taichu Biotech‘s $58m Series A.

United statesLingang life science blue bay fundShanghai lingang economic development groupBoehringer ingelheim venture fundRgenta therapeuticsHighlight capitalTaichu biotechnologyLilly asia venturesVivo capitalMatrix partnersShanghai healthcare capitalBoquan equity investment managementAopeng investmentApricot capitalYijing capitalNeux capital

China Digest: 3D printing firm HBD raises $45m; biotech startup Degron closes $22m

HBD’s Series C round was led by China Life Private Equity Investment

Jing yuLily zouYong cangShanghaitech universityChina iron steel research instituteNuclear power institute of chinaChina life private equity investmentDegron therapeuticsChina life private equityZhongshan cityGuangdong provinceGree electricChina ironSteel research instituteNuclear power instituteLife private equity investment

Degron Therapeutics Raises $22M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

San diegoUnited statesJing yuLily zouYong cangShanghaitech universityDegron therapeuticsMed fine capitalDyee capitalBaidu ventureNeux capitalYuanbio venture

Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

/PRNewswire/ Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable.

Jing yuLily zouYong cangShanghaitech universityDyee capitalBaidu ventureNeux capitalYuanbio ventureDegron therapeuticsMed fine capital

vimarsana © 2020. All Rights Reserved.